Bibliographic information
GuidelineWHO guidelines for malaria, 16 October 2023.
Year of Publication2023
Issuing InstitutionWorld Health Organization
Recommendation
New
Short-course standard high-dose primaquine treatment (2022): To prevent relapse, an additional treatment option of using primaquine 1.0 mg/kg/day for seven days to treat P. vivax or P. ovale malaria is not recommended.
Recommended against
Conditional
Certainty of evidence
Very low
Notes and Remarks
Remark:
- There is a significantly increased risk of serious adverse events (moderate to large undesirable effect) at this daily dosing of the standard high dose.